Time-dependent interaction of ritonavir in chronic use: The power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A

Journal of Pharmaceutical Sciences

Volumn 102, Issue 6, 2013, Pages 2044-2055

  Fukushima, Keizo ^a   Kobuchi, Shinji ^b   Mizuhara, Kazunori ^b   Aoyama, Hiroaki ^b   Takada, Kanji ^b   Sugioka, Nobuyuki ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

ADME; Bioavailability; Cytochrome P450; Disposition; Drug interaction; Intestinal absorption; P glycoprotein; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; RITONAVIR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RAT; TREATMENT DURATION;

EID: 84877920349     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23545     Document Type: Article

References (27)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
2. Karon JM, Fleming PL, Steketee RW, De Cock KM. 2001. HIV in the United States at the turn of the century: An epidemic in transition. Am J Public Health 91:1060-1068.
3. Shetty BV, Kosa MB, Khalil DA, Webber S. 1996. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 40:110-114.
4. van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, Schinkel AH. 2010. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160:1224-1233.
5. Young B, Fischl MA, Wilson HM, Finn TS, Jensen EH, DiNubile MJ, Zeldin RK. 2002. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J Acquir Immune Defic Syndr 31:478-482.
6. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. 2005. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19:685-694.
7. Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A. 2006. Atazanavir and lopinavir/ritonavir: Pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 20:1131-1139.
8. Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ. 2001. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 90:1829-1837.
9. Kageyama M, Namiki H, Fukushima H, Terasaka S, Togawa T, Tanaka A, Ito Y, Shibata N, Takada K. 2005. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull 28:130-137.
10. Fukushima K, Haraya K, Terasaka S, Ito Y, Sugioka N, Takada K. 2008. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats. Biol Pharm Bull 31:1209-1214.
11. Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM. 2007. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 81:69-75.
12. van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW. 2006. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46:758-767.
13. Benet LZ, Cummins CL, Wu CY. 2004. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9.
14. Sweatman TW, Seshadri R, Israel M. 1990. Metabolism and elimination of rhodamine 123 in the rat. Cancer Chemother Pharmacol 27:205-210.
15. Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M. 2001. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. Drug Metab Dispos 29:145-151.
16. Kageyama M, Namiki H, Fukushima H, Ito Y, Shibata N, Takada K. 2005. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull 28:316-322.
17. Kageyama M, Fukushima K, Togawa T, Fujimoto K, Taki M, Nishimura A, Ito Y, Sugioka N, Shibata N, Takada K. 2006. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol Pharm Bull 29:779-784.
18. Higashikawa F, Murakami T, Kaneda T, Kato A, Takano M. 1999. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol 51:67-72.
19. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblatt DJ. 2002. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228-1237.
20. Strelevitz TJ, Foti RS, Fisher MB. 2006. In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334-1341.
21. Qi JW, Nakamura K, Hosokawa S, Okada Y, Horiuchi R, Yamamoto K. 2005. Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John's wort. Biol Pharm Bull 28:1467-1471.
22. Matsuda K, Nishimura Y, Kurata N, Iwase M, Yasuhara H. 2007. Effects of continuous ingestion of herbal teas on intestinal CYP3A in the rat. J Pharmacol Sci 103:214-221.
23. Lam JL, Shugarts SB, Okochi H, Benet LZ. 2006. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther 319:864-870.
24. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD. 2006. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52-60.
25. Aoki M, Okudaira K, Haga M, Nishigaki R, Hayashi M. 2010. Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. Drug Metab Dispos 38:1183-1188.
26. Curran A, Gutirerrez M, Deig E, Mateo G, Lopez RM, Imaz A, Crespo M, Ocaña I, Domingo P, Ribera E. 2010. Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. J Antimicrob Chemother 65:2195-2203.
27. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Wirtz V, Lataillade M, Absalon J, McGrath D, CASTLE Study Team. 2010. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-Week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 53:323-332.